Description: Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.
Home Page: www.intellipharmaceutics.com
IPCI Technical Analysis
30 Worcester Road
Toronto,
ON
M9W 5X2
Canada
Phone:
416 798 3001
Officers
| Name | Title |
|---|---|
| Dr. Isa Odidi MBA, Ph.D. | Co-Founder, Chairman, CEO & Co-Chief Scientific Officer |
| Dr. Amina Odidi Ph.D. | Pres, COO, Co-Chief Scientific Officer, Acting CFO & Exec. Director |
| Dr. Patrick N. Yat Ph.D. | Vice-Pres of Chemistry & Analytical Services |
| Fazayill Shaideen | Controller |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 91.8069 |
| IPO Date: | |
| Fiscal Year End: | November |
| Full Time Employees: | 11 |